Oberland Capital, a private investment firm, agreed to invest $320m in ImmunityBio, a clinical-stage immunotherapy company. “This transaction raises significant capital for the Company to support important growth plans, yet with limited equity dilution and with a cap on total payments tied to the initial investment. Besides providing a capital source at a key inflection point for ImmunityBio, this investment demonstrates strong confidence by Oberland Capital in our future, and in particular in the potential value of Anktiva in bladder cancer, as well as the direction of our clinical pipeline,” Richard Adcock, ImmunityBio CEO and President.